If you can't view this video, your browser does not support HTML5 videos
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with high-risk disease treated with ibrutinib.
1 year